Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer
暂无分享,去创建一个
Okyaz Eminaga | Bernhard Breil | Axel Semjonow | Martin Boegemann | A. Semjonow | B. Breil | O. Eminaga | Omran Al-Hamad | M. Boegemann | Omran Al-Hamad | Okyaz Eminaga
[1] John T. Wei,et al. Selective detection of histologically aggressive prostate cancer , 2012, Cancer.
[2] S. Edge. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual , 2002 .
[3] P. Stattin,et al. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. , 2014, The Journal of urology.
[4] R. Cohen,et al. Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma. , 1998, British journal of urology.
[5] Heng-Tze Cheng,et al. Wide & Deep Learning for Recommender Systems , 2016, DLRS@RecSys.
[6] A. Semjonow,et al. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml. , 2014, Urologic oncology.
[7] A. Partin,et al. Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge. , 1989, The Journal of urology.
[8] J. Malin,et al. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer , 2010, Supportive Care in Cancer.
[9] Aaron J Fisher,et al. A Bayesian hierarchical model for prediction of latent health states from multiple data sources with application to active surveillance of prostate cancer , 2015, Biometrics.
[10] Hartwig Huland,et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. , 2003, The Journal of urology.
[11] Lars Stegger,et al. Concept and implementation of a single source information system in nuclear medicine for myocardial scintigraphy (SPECT-CT data) , 2010, Thrombosis and Haemostasis.
[12] Jianfeng Xu,et al. Using graded response model for the prediction of prostate cancer risk , 2012, Human Genetics.
[14] T. Choueiri,et al. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. , 2015, The Journal of urology.
[15] Jimmy Ba,et al. Adam: A Method for Stochastic Optimization , 2014, ICLR.
[16] H. G. van der Poel,et al. PREDICT: model for prediction of survival in localized prostate cancer , 2015, World Journal of Urology.
[17] Geoffrey E. Hinton,et al. Deep Learning , 2015, Nature.
[18] V. R. McCready,et al. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[19] A W Partin,et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.
[20] J. Brooks,et al. Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer , 2014, Pathology.
[21] Thomas Wiegel,et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.
[22] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[23] Thomas Yu,et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. , 2017, The Lancet. Oncology.
[24] Nitish Srivastava,et al. Dropout: a simple way to prevent neural networks from overfitting , 2014, J. Mach. Learn. Res..
[25] L. Egevad,et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.
[26] Peter Bankhead,et al. QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.
[27] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.
[28] Jing Zhang,et al. Using support vector machine analysis to assess PartinMR: A new prediction model for organ‐confined prostate cancer , 2018, Journal of magnetic resonance imaging : JMRI.
[29] M. Moerland,et al. Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. , 2016, Brachytherapy.
[30] John A. W. McCall,et al. Machine learning for improved pathological staging of prostate cancer: A performance comparison on a range of classifiers , 2012, Artif. Intell. Medicine.
[31] Giovanni Acampora,et al. Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model , 2016, PloS one.
[32] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[33] Sohee Kim,et al. Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population , 2017, Cancer research and treatment : official journal of Korean Cancer Association.
[34] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[35] Gary K. Chen,et al. Reproducibility, Performance, and Clinical Utility of a Genetic Risk Prediction Model for Prostate Cancer in Japanese , 2012, PloS one.
[36] Ronald C. Chen,et al. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients. , 2015, International journal of radiation oncology, biology, physics.
[37] M. Kattan,et al. Making and evaluating a statistical prediction model for the absolute risk of prostate cancer recurrence , 2011, Cancer.
[38] M. Leeflang,et al. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. , 2008, Clinical chemistry.
[39] M. Kattan,et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. , 2010, European urology.
[40] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[41] David C. Miller,et al. askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men. , 2019, European urology.
[42] Hua Tan,et al. Prediction of treatment efficacy for prostate cancer using a mathematical model , 2016, Scientific Reports.
[43] Doris Xin,et al. DWCox: A density-weighted Cox model for outlier-robust prediction of prostate cancer survival , 2016, F1000Research.
[44] R W Veltri,et al. Prediction of prostate carcinoma stage by quantitative biopsy pathology , 2001, Cancer.
[45] S. Aedo,et al. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells , 2016, BJU international.
[46] U. Jelen,et al. The influence of the local effect model parameters on the prediction of the tumor control probability for prostate cancer , 2014, Physics in medicine and biology.
[47] Hartwig Huland,et al. Quantitative biopsy pathology for the prediction of pathologically organ‐confined prostate carcinoma , 2003, Cancer.
[48] F. Wawroschek,et al. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate‐specific antigen (PSA) level of ≤10 ng/mL and biopsy Gleason score of ≤6, and their influence on PSA progression‐free survival after radical prostatectomy , 2006, BJU international.
[49] Yan-feng Li,et al. The establishment and evaluation of a new model for the prediction of prostate cancer , 2017, Medicine.
[50] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[51] Misop Han,et al. Prediction of pathological stage based on clinical stage, serum prostate‐specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era , 2017, BJU international.
[52] Scott H. Kurtzman,et al. AJCC cancer staging atlas , 2006 .
[53] Fleur Fritz,et al. HIS-based Kaplan-Meier plots - a single source approach for documenting and reusing routine survival information , 2011, BMC Medical Informatics Decis. Mak..
[54] M. Menon,et al. Population‐Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients , 2017, The Prostate.
[55] Martin Dugas,et al. HIS-based electronic documentation can significantly reduce the time from biopsy to final report for prostate tumours and supports quality management as well as clinical research , 2009, BMC Medical Informatics Decis. Mak..
[56] Okyaz Eminaga,et al. CMDX©-based single source information system for simplified quality management and clinical research in prostate cancer , 2012, BMC Medical Informatics and Decision Making.
[57] C. Roehrborn,et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation , 2006, BJU international.
[58] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[59] A. Young. Recurrence. , 2020, JAMA.
[60] M. Roobol,et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.
[61] A. Semjonow,et al. Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies , 2015, BJU international.